bioMerieux (OTCMKTS:BMXMF) Hits New 12-Month Low – Should You Sell?
by Amy Steele · The Cerbat GembioMerieux (OTCMKTS:BMXMF – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $81.52 and last traded at $81.52, with a volume of 58 shares changing hands. The stock had previously closed at $103.41.
Analyst Ratings Changes
Several equities research analysts recently issued reports on BMXMF shares. BNP Paribas Exane lowered shares of bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a report on Friday. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, bioMerieux currently has an average rating of “Hold”.
View Our Latest Stock Report on bioMerieux
bioMerieux Stock Performance
The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The stock’s fifty day simple moving average is $109.90 and its two-hundred day simple moving average is $119.36.
About bioMerieux
bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.